Abstract | OBJECTIVE: The goal of this study was to estimate the clinical activity of paclitaxel in patients with persistent or recurrent carcinosarcoma of the uterus who have failed other treatments. METHODS: The Gynecologic Oncology Group (GOG) conducted a phase II study of paclitaxel 170 mg/m(2) (135 mg/m(2) in those with prior irradiation) intravenously every 3 weeks in patients with histologic confirmation of carcinoma and measurable disease who had failed appropriate local therapy. RESULTS: A total of 53 patients were entered into the study between September 1994 and January 1997; 44 patients were evaluable for response. The median age of the patients treated was 65 years (range: 38-79). Twenty-six patients had heterologous mixed mesodermal tumors ( MMTs) and 18 patients had homologous tumors. A median of three courses were administered (range: 1-18). Fifteen patients had previous radiation therapy and 33 patients had failed prior chemotherapy. Eight patients (18.2%) had a response to paclitaxel: four patients had a complete response and four had a partial response. Neutropenia was the most common toxic effect. CONCLUSIONS:
|
Authors | J P Curtin, J A Blessing, J T Soper, K DeGeest |
Journal | Gynecologic oncology
(Gynecol Oncol)
Vol. 83
Issue 2
Pg. 268-70
(Nov 2001)
ISSN: 0090-8258 [Print] United States |
PMID | 11606082
(Publication Type: Clinical Trial, Clinical Trial, Phase II, Journal Article, Multicenter Study, Research Support, U.S. Gov't, P.H.S.)
|
Copyright | Copyright 2001 Academic Press. |
Chemical References |
- Antineoplastic Agents, Phytogenic
- Paclitaxel
|
Topics |
- Adult
- Aged
- Antineoplastic Agents, Phytogenic
(adverse effects, therapeutic use)
- Carcinosarcoma
(drug therapy)
- Drug Administration Schedule
- Female
- Humans
- Infusions, Intravenous
- Middle Aged
- Neoplasm Recurrence, Local
(drug therapy)
- Paclitaxel
(adverse effects, therapeutic use)
- Uterine Neoplasms
(drug therapy)
|